Vaccination Programs for Endemic Infections: Modelling Real versus Apparent Impacts of Vaccine and Infection Characteristics

Scientific Reports

Volumn 5, Issue , 2015, Pages

  Ragonnet, Romain ^a   Trauer, James M ^a,b,c   Denholm, Justin T ^b,c,d   Geard, Nicholas L ^c   Hellard, Margaret ^a   McBryde, Emma S ^a,b,c  

^a BURNET INSTITUTE   (Australia)

^b ROYAL MELBOURNE HOSPITAL   (Australia)

^c UNIVERSITY OF MELBOURNE   (Australia)

^d Victorian Tuberculosis Program Melbourne Health   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

VACCINE;

COMMUNICABLE DISEASE CONTROL; COMPUTER SIMULATION; HUMAN; PREVENTIVE HEALTH SERVICE; THEORETICAL MODEL; VACCINATION;

COMMUNICABLE DISEASE CONTROL; COMPUTER SIMULATION; HUMANS; IMMUNIZATION PROGRAMS; MODELS, THEORETICAL; VACCINATION; VACCINES;

EID: 84945217639     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep15468     Document Type: Article

References (43)

1. Greenwood, B. The contribution of vaccination to global health: past, present and future. Philos Trans R Soc Lond B Biol Sci 369, 20130433 (2014).
2. Moutou, F. The second eradication: Rinderpest. Bull Soc Pathol Exot 107, 137-138 (2014).
3. Fenner, F. A successful eradication campaign. Global eradication of smallpox. Rev Infect Dis 4, 916-930 (1982).
4. Wilson, A. T., Henderson, I. R., Moore, E. J., Heywood, S. N. Whooping-Cough: Difficulties in Diagnosis and Ineffectiveness of Immunization. Br Med J 2, 623-626 (1965).
5. Najera, J. A., Gonzalez-Silva, M., Alonso, P. L. Some lessons for the future from the Global Malaria Eradication Programme (1955-1969). PLoS Med 8, e1000412 (2011).
6. Poland, G. A. Pertussis outbreaks and pertussis vaccines: new insights, new concerns, new recommendations? Vaccine 30, 6957-6959 (2012).
7. Mangtani, P. et al. Protection by BCG vaccine against tuberculosis: a systematic review of randomized controlled trials. Clinical infectious diseases: an official publication of the Infectious Diseases Society of America 58, 470-480 (2014).
8. Haber, M. Estimation of the direct and indirect effects of vaccination. Statistics in medicine 18, 2101-2109 (1999).
9. Wang, H. et al. Meta-analysis of vaccine effectiveness of mumps-containing vaccine under different immunization srategies in China. Vaccine 32, 4806-4812 (2014).
10. Colditz, G. A. et al. Efficacy of BCG vaccine in the prevention of tuberculosis. Meta-analysis of the published literature. Jama 271, 698-702 (1994).
11. Tazhibi, M., Hajivandi, A., Tafti, A. D., Fallahzadeh, H. The efficacy of hepatitis B vaccine in Iranian population: A systematic review and meta-analysis. J Educ Health Promot 3, 53 (2014).
12. Pannaraj, P. S. et al. School-Located Influenza Vaccination Decreases Laboratory-Confirmed Influenza and Improves School Attendance. Clin Infect Dis 59, 325-332 (2014).
13. Vestrheim, D. F. et al. Indirect effect of conjugate pneumococcal vaccination in a 2+ 1 dose schedule. Vaccine 28, 2214-2221 (2010).
14. Harper, D. M. et al. Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial. Lancet 367, 1247-1255 (2006).
15. Skinner, S. R. et al. Efficacy, safety, and immunogenicity of the human papillomavirus 16/18 AS04-adjuvanted vaccine in women older than 25 years: 4-year interim follow-up of the phase 3, double-blind, randomised controlled VIVIANE study. Lancet 384, 2213-2227 (2014).
16. Hildesheim, A. et al. Efficacy of the HPV-16/18 vaccine: final according to protocol results from the blinded phase of the randomized Costa Rica HPV-16/18 vaccine trial. Vaccine 32, 5087-5097 (2014).
17. Zhu, F. C. et al. Efficacy, immunogenicity and safety of the HPV-16/18 AS04-adjuvanted vaccine in healthy Chinese women aged 18-25 years: results from a randomized controlled trial. International journal of cancer. Journal international du cancer 135, 2612-2622 (2014).
18. Bonten, M. J. et al. Polysaccharide conjugate vaccine against pneumococcal pneumonia in adults. N Engl J Med 372, 1114-1125 (2015).
19. Tregnaghi, M. W. et al. Efficacy of pneumococcal nontypable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) in young Latin American children: A double-blind randomized controlled trial. PLoS Med 11, e1001657 (2014).
20. Halloran, M. E., Struchiner, C. J., Longini, I. M., Jr. Study designs for evaluating different efficacy and effectiveness aspects of vaccines. Am J Epidemiol 146, 789-803 (1997).
21. Halloran, M. E., Longini, I. M., Jr., Struchiner, C. J. Design and interpretation of vaccine field studies. Epidemiologic reviews 21, 73-88 (1999).
22. Longini, I. M., Jr., Sagatelian, K., Rida, W. N., Halloran, M. E. Optimal vaccine trial design when estimating vaccine efficacy for susceptibility and infectiousness from multiple populations. Stat Med 17, 1121-1136 (1998).
23. Halloran, M. E., Longini, I. M., Jr., Struchiner, C. J. Estimability and interpretation of vaccine efficacy using frailty mixing models. Am J Epidemiol 144, 83-97 (1996).
24. Shim, E., Galvani, A. P. Distinguishing vaccine efficacy and effectiveness. Vaccine 30, 6700-6705 (2012).
25. Baussano, I., Garnett, G., Segnan, N., Ronco, G., Vineis, P. Modelling patterns of clearance of HPV-16 infection and vaccination efficacy. Vaccine 29, 1270-1277 (2011).
26. Becker, N. G., Britton, T., O'Neill, P. D. Estimating vaccine effects on transmission of infection from household outbreak data. Biometrics 59, 467-475 (2003).
27. Gomes, M. G., White, L. J., Medley, G. F. Infection, reinfection, and vaccination under suboptimal immune protection: epidemiological perspectives. J Theor Biol 228, 539-549 (2004).
28. Gomes, M. G., Franco, A. O., Gomes, M. C., Medley, G. F. The reinfection threshold promotes variability in tuberculosis epidemiology and vaccine efficacy. Proc Biol Sci 271, 617-623 (2004).
29. Hogea, C., van Effelterre, T., Acosta, C. J. A basic dynamic transmission model of Staphylococcus aureus in the US population. Epidemiology and infection 142, 468-478 (2014).
30. Ribassin-Majed, L., Lounes, R., Clemencon, S. Deterministic modelling for transmission of Human Papillomavirus 6/11: impact of vaccination. Math Med Biol 31, 125-49 (2013).
31. Ejima, K., Aihara, K., Nishiura, H. The impact of model building on the transmission dynamics under vaccination: observable (symptom-based) versus unobservable (contagiousness-dependent) approaches. PloS one 8, e62062 (2013).
32. Shim, E., Galvani, A. P. Impact of transmission dynamics on the cost-effectiveness of rotavirus vaccination. Vaccine 27, 4025-4030 (2009).
33. Kribs-Zaleta, C. M., Velasco-Hernandez, J. X. A simple vaccination model with multiple endemic states. Math Biosci 164, 183-201 (2000).
34. Lanzieri, T. M., Bialek, S. R., Ortega-Sanchez, I. R., Gambhir, M. Modeling the potential impact of vaccination on the epidemiology of congenital cytomegalovirus infection. Vaccine 32, 3780-6 (2014).
35. Vanska, S. et al. Impact of vaccination on 14 high-risk HPV type infections: a mathematical modelling approach. PloS one 8, e72088 (2013).
36. Lugner, A. K., van Boven, M., de Vries, R., Postma, M. J., Wallinga, J. Cost effectiveness of vaccination against pandemic influenza in European countries: mathematical modelling analysis. BMJ 345, e4445 (2012).
37. Choi, Y. H. et al. Transmission dynamic modelling of the impact of human papillomavirus vaccination in the United Kingdom. Vaccine 28, 4091-4102 (2010).
38. Halloran, M. E., Haber, M., Longini, I. M., Jr. Interpretation and estimation of vaccine efficacy under heterogeneity. Am J Epidemiol 136, 328-343 (1992).
39. Rahman, M. S. Estimating vaccine efficacy under the heterogeneity of vaccine action in a nonrandomly mixing population. J Biopharm Stat 23, 394-412 (2013).
40. Trauer, J. M., Denholm, J. T., McBryde, E. S. Construction of a mathematical model for tuberculosis transmission in highly endemic regions of the Asia-Pacific. Journal of theoretical biology 358, 74-84 (2014).
41. Campbell, P. et al. Increased population prevalence of low pertussis toxin antibody levels in young children preceding a record pertussis epidemic in Australia. PLoS One 7, e35874 (2012).
42. Fine, P. E., Vynnycky, E. The effect of heterologous immunity upon the apparent efficacy of (e.g. BCG) vaccines. Vaccine 16, 1923-1928 (1998).
43. Lehtinen, M. et al. Characteristics of a cluster-randomized phase IV human papillomavirus vaccination effectiveness trial. Vaccine 33, 1284-1290 (2015).